Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

195.93 +0.68 (+0.35%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday ↗
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
News headline image
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025 ↗
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
News headline image
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
News headline image
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 15 Takes On Johnson & Johnson ↗
 
Via Benzinga
News headline image
Why NYSE:JNJ is a Top Pick for Dividend Investors. ↗
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
News headline image
5 Unbeatable Stocks I'm Eager to Buy in 2025 ↗
These value, growth, and income stocks are incredibly cheap in a historically pricey stock market. 
Via The Motley Fool
News headline image
10 Dividend Stocks For Intergenerational Wealth ↗
The Dividend Aristocrats broadly have durable competitive advantages, and long-term growth. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise ↗
Johnson & Johnson (NYSE:JNJ) enters bearish pattern, death cross, but strong dividends & strategic moves in dermatology provide long-term appeal. 
Via Benzinga
News headline image
The Smartest Dividend Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
10 Buy And Hold Forever Dividend Stocks ↗
The following 10 stocks represent Dividend Kings that can continue to raise their dividends for decades to come. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025 ↗
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip... 
Via Benzinga
News headline image
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks ↗
Via The Motley Fool
News headline image
The Options Market Is Pointing Us At Four Dividend Stocks Right Now ↗
It’s a good idea to look at stocks that can give us what we need in the absence of a rally. 
Via Talk Markets
Topics Bonds Commodities Stocks / Equities
News headline image
5 Lowest Volatility Dividend Stocks ↗
Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
News headline image
The Smartest Dividend Stocks to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer ↗
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy 
Via Benzinga
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over ↗
Via The Motley Fool
Topics Stocks
News headline image
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix ↗
When asked about Advanced Micro Devices, Cramer asks: "But can we just remember Lisa Su has built an amazing company?" 
Via Benzinga
News headline image
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance ↗
Jim Cramer expressed strong buying conviction for Netflix Inc. during Wednesday's Lightning Round on "Mad Money," as the streaming giant's shares traded near $934 amid broader tech market strength. 
Via Benzinga
News headline image
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap ↗
Only 25 listed companies have a higher market capitalization than Elon Musk's skyrocketing net worth. 
Via Benzinga
News headline image
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex ↗
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year? ↗
Via The Motley Fool
Topics Stocks
News headline image
Top Analyst Reports For Home Depot, Johnson & Johnson & Salesforce ↗
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc., Johnson & Johnson, and Salesforce, Inc., as well as two micro-cap stocks, Preformed Line... 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.